Saturn V Capital Management LP 13F holdings, Q2 2025
Holdings as of June 30, 2025 · filings on SEC EDGAR · latest filing →
Saturn V Capital Management LP disclosed 24 US equity positions worth $246.8m in its Q2 2025 13F filing. The largest position was JAZZ at 8.9% of the reported book, followed by IRON and AMLX. Against the Q1 2025 filing, it opened 5 new positions, added to 10 and reduced 9 among the top 24 holdings.
What did Saturn V Capital Management LP own in Q2 2025? Top 24 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2025 |
|---|---|---|---|---|---|---|---|
| 1 | JAZZ JAZZ PHARMACEUTICALS PLC | Healthcare | 8.9% | $22.0m | 206,952 | – | new |
| 2 | IRON DISC MEDICINE INC | Healthcare | 8.5% | $21.0m | 396,115 | -24% | reduced |
| 3 | AMLX AMYLYX PHARMACEUTICALS INC | Healthcare | 8.5% | $20.9m | 3,260,570 | 34% | added |
| 4 | PCVX VAXCYTE INC | Healthcare | 7.2% | $17.7m | 544,221 | 134% | added |
| 5 | COGT COGENT BIOSCIENCES INC | Healthcare | 6.7% | $16.5m | 2,297,524 | 55% | added |
| 6 | CELC CELCUITY INC | Healthcare | 6.4% | $15.8m | 1,185,520 | 8% | added |
| 7 | CGON CG ONCOLOGY INC | Healthcare | 6.2% | $15.3m | 586,647 | 2% | added |
| 8 | XENE XENON PHARMACEUTICALS INC | Healthcare | 5.9% | $14.7m | 468,364 | 13% | added |
| 9 | DYN DYNE THERAPEUTICS INC | Healthcare | 5.6% | $13.9m | 1,455,429 | – | new |
| 10 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | 5.6% | $13.7m | 290,784 | -15% | reduced |
| 11 | MERUS N V | 4.8% | $11.8m | 224,260 | -31% | reduced | |
| 12 | CNTA CENTESSA PHARMACEUTICALS PLC | 4.2% | $10.4m | 793,327 | 77% | added | |
| 13 | LENZ LENZ THERAPEUTICS INC | Healthcare | 4.1% | $10.0m | 342,312 | – | new |
| 14 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 3.0% | $7.3m | 58,181 | – | new |
| 15 | OCUL OCULAR THERAPEUTIX INC | Healthcare | 2.7% | $6.8m | 728,576 | 22% | added |
| 16 | ASND ASCENDIS PHARMA A/S | Healthcare | 2.7% | $6.6m | 38,191 | -81% | reduced |
| 17 | ARGX ARGENX SE | Healthcare | 2.3% | $5.7m | 10,285 | -26% | reduced |
| 18 | ABVX ABIVAX SA | 1.9% | $4.8m | 622,479 | 13% | added | |
| 19 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 1.9% | $4.7m | 500,551 | -52% | reduced |
| 20 | NEWAMSTERDAM PHARMA COMPANY | 1.6% | $4.0m | 220,695 | 90% | added | |
| 21 | CTNM CONTINEUM THERAPEUTICS INC | 0.5% | $1.3m | 319,348 | -43% | reduced | |
| 22 | REPL REPLIMUNE GROUP INC | Healthcare | 0.5% | $1.2m | 128,917 | – | new |
| 23 | 4XC1 KALVISTA PHARMACEUTICALS INC | 0.3% | $709.9k | 62,793 | -75% | reduced | |
| 24 | SLN SILENCE THERAPEUTICS PLC | 0.1% | $201.5k | 34,737 | -95% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.